Evidence map›Paper›PMID 38237590›Full record

ArticleDevelopmental cell2024

ZFP281 controls transcriptional and epigenetic changes promoting mouse pluripotent state transitions via DNMT3 and TET1.

Xin Huang, Sophie Balmer, Cong Lyu, Yunlong Xiang, Vikas Malik, Hailin Wang, Yu Zhang, Bishuang Cai, Wei Xie, Anna-Katerina Hadjantonakis and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Developmental cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. BRD8 Guards the Pluripotent State by Sensing and Maintaining Histone Acetylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Xin HuangDepartment of Medicine, Columbia Center for Human Development and Stem Cell Therapies, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: xh2200@cumc.columbia.edu.
Sophie BalmerDevelopmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cong LyuResearch Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
Yunlong XiangTsinghua Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.
Vikas MalikDepartment of Medicine, Columbia Center for Human Development and Stem Cell Therapies, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Hailin WangResearch Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
Yu ZhangTsinghua Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China; Obstetrics and Gynecology Hospital, Institute of Reproduction and Development, Fudan University, Shanghai 200082, China.
Bishuang CaiDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Wei XieTsinghua Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.
Anna-Katerina HadjantonakisDevelopmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Hongwei ZhouDepartment of Medicine, Columbia Center for Human Development and Stem Cell Therapies, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Jianlong WangDepartment of Medicine, Columbia Center for Human Development and Stem Cell Therapies, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: jw3925@cumc.columbia.edu.
Columbia University Irving Medical Center · USCenter for Life Sciences · CNChinese Academy of Sciences · CNMemorial Sloan Kettering Cancer Center · USIcahn School of Medicine at Mount Sinai · USObstetrics and Gynecology Hospital of Fudan University · CN

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Mechanisms driving cell fate specification and morphogenesis in the blastocystR01HD094868 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI ANNA-KATERINA HADJANTONAKIS · 2018 to 2026
$4.2M
Phenotyping Early Embryonic Lethal Knockout Mice to Identify Essential Genes with Previously Uncharacterized Roles in Pre-implantation Development, Gastrulation, Turning, and PlacentationR01HD086478 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI HADJANTONAKIS, ANNA-KATERINA · 2016 to 2020
$3.4M
The gut endoderm: origin, formation and fateR01DK127821 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI ANNA-KATERINA HADJANTONAKIS · 2021 to 2026
$3.4M
EHD1-mediated Inflammation and Resolution in AtherosclerosisR01HL167107 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Bishuang Cai · 2023 to 2026
$2.8M
Disturbed Crosstalk between Cholesterol Homeostasis and Inflammation Resolution in NASHR01DK134610 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Bishuang Cai · 2023 to 2026
$2.2M
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cellsR01HD095938 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, JIANLONG · 2018 to 2022
$1.7M
Defining Novel Molecular Pathways to TotipotencyR01HD097268 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, JIANLONG · 2018 to 2022
$1.7M
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesisR01HL146664 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI WANG, JIANLONG, XU, MINGJIANG · 2019 to 2022
$1.7M
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281R01GM129157 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, JIANLONG · 2018 to 2021
$1.3M
SINE-mediated Regulation of mRNA Epitranscriptome for Pluripotency Maintenance and DifferentiationR21HD106263 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HUANG, XIN · 2022 to 2023
$452k
NCI NIH HHS P30 CA008748NHLBI NIH HHS R01 HL146664NHLBI NIH HHS R01 HL167107NICHD NIH HHS R01 HD086478NICHD NIH HHS R01 HD094868NICHD NIH HHS R01 HD095938NICHD NIH HHS R01 HD097268NICHD NIH HHS R21 HD106263NIDDK NIH HHS R01 DK127821NIDDK NIH HHS R01 DK134610NIGMS NIH HHS R01 GM129157
6 · The paper itself

Abstract

The progression from naive through formative to primed in vitro pluripotent stem cell states recapitulates epiblast development in vivo during the peri-implantation period of mouse embryo development. Activation of the de novo DNA methyltransferases and reorganization of transcriptional and epigenetic landscapes are key events that occur during these pluripotent state transitions. However, the upstream regulators that coordinate these events are relatively underexplored. Here, using Zfp281 knockout mouse and degron knockin cell models, we identify the direct transcriptional activation of Dnmt3a/3b by ZFP281 in pluripotent stem cells. Chromatin co-occupancy of ZFP281 and DNA hydroxylase TET1, which is dependent on the formation of R-loops in ZFP281-targeted gene promoters, undergoes a "high-low-high" bimodal pattern regulating dynamic DNA methylation and gene expression during the naive-formative-primed transitions. ZFP281 also safeguards DNA methylation in maintaining primed pluripotency. Our study demonstrates a previously unappreciated role for ZFP281 in coordinating DNMT3A/3B and TET1 functions to promote pluripotent state transitions.

Indexed as

Epigenesis, GeneticPluripotent Stem CellsAnimalsCell DifferentiationChromatinDNADNA-Binding ProteinsDNA MethylationGerm LayersMiceProto-Oncogene ProteinsTranscription FactorsChromatinDNADNA-Binding ProteinsProto-Oncogene ProteinsTET1 protein, mouseTranscription FactorsZfp281 protein, mouseDNA methylationDNMT3formativenaivepluripotencyprimedR-loopTET1ZFP281

Identifiers

PMID38237590
PMCPMC10923053
OpenAlexW4390942515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.